Molecular Partners‘ multiple myeloma treatment candidate MP0250 showed positive preliminary safety and effectiveness results in an ongoing Phase 2 clinical study, according to the biopharmaceutical…
An old blood-pressure-lowering therapy known as a diuretic killed multiple myeloma cells in a lab and in mice, including those resistant to current treatments, Spanish researchers…
The Phase 1b clinical trial called MUK eleven (NCT03015922) testing Reolysin (pelareorep) as a combination therapy for relapsing myeloma patients has dosed its first…
Treatment with Empliciti (elotuzumab) plus Revlimid (lenalidomide) and dexamethasone (ELd) in patients with relapsed/refractory multiple myeloma (RRMM) continued to show effectiveness in the Phase 3…